Raphael Genolet
Overview
Explore the profile of Raphael Genolet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1418
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiffelle J, Barras D, Petremand R, Orcurto A, Bobisse S, Arnaud M, et al.
Immunity
. 2024 Sep;
57(10):2466-2482.e12.
PMID: 39276771
Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) has inconsistent clinical responses. To better understand determinants of therapeutic success, we tracked TIL clonotypes from baseline tumors to...
2.
Petremand R, Chiffelle J, Bobisse S, Perez M, Schmidt J, Arnaud M, et al.
Nat Biotechnol
. 2024 Jun;
PMID: 38918618
No abstract available.
3.
Petremand R, Chiffelle J, Bobisse S, Perez M, Schmidt J, Arnaud M, et al.
Nat Biotechnol
. 2024 May;
PMID: 38714897
A central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct transcriptomic profile of tumor-reactive T cells relative to...
4.
Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, et al.
Nat Cancer
. 2023 Nov;
5(2):240-261.
PMID: 37996514
Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested extensively for therapeutic vaccination in cancer,...
5.
Bobisse S, Bianchi V, Tanyi J, Sarivalasis A, Missiaglia E, Petremand R, et al.
Nat Cancer
. 2023 Sep;
4(10):1410-1417.
PMID: 37735588
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we...
6.
Fallet B, Foglierini M, Porret R, Alcaraz-Serna A, Sauvage C, Jenelten R, et al.
J Infect
. 2023 Jun;
87(2):111-119.
PMID: 37321353
Objectives: Intradermal skin test (IDT) with mRNA vaccines may represent a simple, reliable, and affordable tool to measure T cell response in immunocompromised patients who failed to mount serological responses...
7.
Romanens L, Chaskar P, Marcone R, Ryser S, Tille J, Genolet R, et al.
Int J Cancer
. 2023 Jun;
153(9):1568-1578.
PMID: 37306359
The spatial distribution of tumor-infiltrating lymphocytes (TIL) predicts breast cancer outcome and response to systemic therapy, highlighting the importance of an intact tissue structure for characterizing tumors. Here, we present...
8.
Schmidt J, Chiffelle J, Perez M, Magnin M, Bobisse S, Arnaud M, et al.
Nat Commun
. 2023 Jun;
14(1):3188.
PMID: 37280206
The success of cancer immunotherapy depends in part on the strength of antigen recognition by T cells. Here, we characterize the T cell receptor (TCR) functional (antigen sensitivity) and structural...
9.
Genolet R, Bobisse S, Chiffelle J, Arnaud M, Petremand R, Queiroz L, et al.
Cell Rep Methods
. 2023 May;
3(4):100459.
PMID: 37159666
T cell receptor (TCR) technologies, including repertoire analyses and T cell engineering, are increasingly important in the clinical management of cellular immunity in cancer, transplantation, and other immune diseases. However,...
10.
Racle J, Guillaume P, Schmidt J, Michaux J, Larabi A, Lau K, et al.
Immunity
. 2023 Apr;
56(6):1359-1375.e13.
PMID: 37023751
CD4 T cells orchestrate the adaptive immune response against pathogens and cancer by recognizing epitopes presented on class II major histocompatibility complex (MHC-II) molecules. The high polymorphism of MHC-II genes...